Hims & Hers Health, Inc. (HIMS)
Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside
With the health care sector remaining mostly flat several weeks into 2026, one of last year's success stories has turned into an investor nightmare as shares of Hims & Hers Health NYSE: HIMS continue to plummet from their record highs.
Hims & Hers Accelerates AI Preventive Care and Platform Strategy
HIMS is accelerating AI-driven preventive care with new menopause, low testosterone and multi-cancer testing, deepening its personalized digital health platform.
Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint
Hims & Hers (NYSE:HIMS) announced on Thursday that it has entered a definitive agreement to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. The acquisition is expected to strengthen Hims & Hers' international presence and expand its personalized healthcare offerings.
Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
HIMS fourth-quarter 2025 results are likely to benefit from new specialties and global expansion, but higher costs and GLP-1 scrutiny could cloud earnings.
Hims & Hers is spending more than $1 billion in a push to expand globally
Shares of Hims & Hers Health rallied in early Thursday trading, after the health-and-wellness platform announced a deal to buy an Australia-based telehealth provider.
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion
Hims & Hers Health said on Thursday it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion, as the U.S. telehealth platform seeks to broaden its personalized care business into new international markets.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $15.84, marking a -2.64% move from the previous day.
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff
Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of February 13.
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, according to data shared with Reuters by Hazeltree.
US could take action including fines against Hims after brief Wegovy copy launch
The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, attorneys and other experts told Reuters.
